Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986331 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part 1 Single Ascending Dose (SAD): Panel 1 | EXPERIMENTAL | - |
| Part 1 SAD: Panel 2 | EXPERIMENTAL | - |
| Part 1 SAD: Panel 3 | EXPERIMENTAL | - |
| Part 1 SAD: Panel 4 | EXPERIMENTAL | - |
| Part 1 SAD: Panel 5 | EXPERIMENTAL | - |
| Part 1 SAD: Panel 6 | EXPERIMENTAL | - |
| Part 1 SAD: Optional Split-dose Panel | EXPERIMENTAL | - |
| Part 2 Multiple Ascending Dose (MAD): Panel 1 | EXPERIMENTAL | - |
| Part 2 MAD: Panel 2 | EXPERIMENTAL | - |
| Part 2 MAD: Panel 3 | EXPERIMENTAL | - |
| Part 2 MAD: Panel 4 | EXPERIMENTAL | - |
| Part 2 MAD: Optional (to be determined) Panel | EXPERIMENTAL | - |
| Part 3 MAD in Japanese Participants (J-MAD): Panel 1 | EXPERIMENTAL | - |
| Part 3 J-MAD: Panel 2 | EXPERIMENTAL | - |
| Part 3 J-MAD: Panel 3 | EXPERIMENTAL | - |
| Part 3 J-MAD: Optional (to be determined) Panel | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986331 | DRUG | Specified dose on specified days |
| Placebo, Matching BMS-986331 | OTHER | Specified dose on specified days |
Inclusion Criteria: * No clinically significant deviations in medical history, physical examination, ECGs, vital signs, and clinical laboratory determinations * A body mass index of 18 - 32 kg/m2, inclusive * Women and men must agree to follow specific methods of contraception, if applicable For J...
BMS-986331 is an investigational small molecule being developed by Bristol-Myers Squibb Company. It has been studied in a Phase 1 clinical trial in healthy adult participants. The specific disease or condition it is intended to treat has not been publicly disclosed.
Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY, is the developer of BMS-986331. The company sponsored the Phase 1 trial evaluating the compound in healthy participants.
BMS-986331 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The compound has not been approved by the FDA and remains investigational.
BMS-986331 has been evaluated in one clinical trial, NCT04444050, titled a Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986331 in Healthy Participants. The Phase 1 trial enrolled 48 participants in the United States and is completed.
The Phase 1 trial NCT04444050 was a randomized, double-blind, controlled study in healthy adult participants aged 18 years and older. It enrolled 48 participants across sites in the United States and assessed safety, tolerability, drug levels, and drug effects.